Baxalta Wins New Try at Hemophilia Drug Patent Infringement Suit

Genentech Inc. will have to face revived claims that its hemophilia treatment infringes Baxalta Inc.'s patent for an antibody that increases blood-clotting activity.

The U.S. Court of Appeals for the Federal Circuit held that a lower court misconstrued two key terms in the patent. The interpretation led the parties to agree Genentech didn’t infringe so Baxalta could appeal.

The decision overturns a ruling by Federal Circuit Judge Timothy B. Dyk, who was serving as a visiting judge for the case in the U.S. District Court for the District of Delaware. Dyk has volunteered 16 times to hear cases on lower ...